TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03711500
Drug: D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
Study: NCT03711500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
Study: NCT00002953
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01042665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT03113708
Drug: Heparin Sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
Study: NCT02171585
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01954615
Drug: 20 mg ACT-281959 prodrug formulation I (Group B)
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01081795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
Study: NCT02486055
Drug: BPM31510 Oral Nanosuspension 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
Study: NCT00920660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.
Study: NCT00920660
Drug: 0.25g SRT2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.
Study: NCT00920660
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the last treatment period, subjects will receive 30 mg open-label prednisolone.
Study: NCT00920660
Drug: 1g SRT2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.
Study: NCT02748707
Drug: Arm1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
Study: NCT02748707
Drug: Arm 2
Normalized name: Surgitube Arm 2 5/8x50"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
Study: NCT01146106
Drug: Pravastatin Sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin Sodium Tablets 80 mg
Study: NCT00456014
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subsequent to escitalopram trial, non-remitters will be offered pharmacotherapy with desipramine. Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
Study: NCT02833103
Drug: Danshu Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshu Capsules (0.9g potid/day) for three months by oral
Study: NCT03217838
Drug: AZD2811
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2811 will be administered by IV infusion with the specified dose level as reported in arms in 28-day cycles.
Study: NCT01533376
Drug: Preservative free artificial tear gel.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative free artificial tear gel applied topically twice a day.
Study: NCT01954615
Drug: Placebo (Groups A to F)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04824586
Drug: Fast-acting human insulin
Normalized name: Insulins and analogues for injection, fast-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both patients in the infusion or bolus group received their dose of insulin. The protocol of the insulin regimen and its related details were carried out according to the standard recommendations in a hospital where the trial done.
Study: NCT00516737
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo; one dose, treatment of a single migraine attack
Study: NCT00968851
Drug: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms: 1
Study: NCT00968851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm: 3
Study: NCT00968851
Drug: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms: 2
Study: NCT01547325
Drug: NanoDOX 1% doxycycline monohydrate Hydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% doxycycline monohydrate hydrogel
Study: NCT01547325
Drug: placebo hydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo hydrogel
Study: NCT00603759
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg qid
Study: NCT00603759
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cap qid
Study: NCT02926950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet. Route of administration: oral.
Study: NCT00002764
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00366522
Drug: LXR-623
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02561091
Drug: AM-111 0.4 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02561091
Drug: AM-111 0.8 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03682601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquaphor/vehicle
Study: NCT01995071
Drug: ABT-493
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01995071
Drug: ABT-530
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01995071
Drug: ABT-450/r/ABT-267, ABT-333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study: NCT01157078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral, twice daily for 8 weeks
Study: NCT01020474
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsules twice daily.
Study: NCT01490567
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 5mg/d
Study: NCT03872401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously using an autoinjector pen.
Study: NCT04257461
Drug: Fluoropyrimidine
Normalized name: Fluoropyrimidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.
Study: NCT02485145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo, which consists of the VersaPro cream, will be utilized in the study.
Study: NCT01891487
Drug: Track B
Normalized name: GNP TRUEtrack Blood Glucose System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refresh Tears applied to eyebrows
Study: NCT00835146
Drug: COPEGUS™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 200 mg, single-dose fasting
Study: NCT00236535
Drug: tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00812214
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet every night at bedtime
Study: NCT01480297
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salsalate 3 grams daily (1 gram TID with meals)
Study: NCT01008280
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill tid
Study: NCT04404361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching pacritinib 100 mg capsules
Study: NCT02944448
Drug: CR845 tablet 1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR845 tablets will be provided as 1 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
Study: NCT02944448
Drug: CR845 tablet 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR845 tablets will be provided as 2.5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
Study: NCT02944448
Drug: CR845 tablet 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR845 tablets will be provided as 5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
Study: NCT02944448
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
Study: NCT01334034
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.
Study: NCT04859361
Drug: Aldara 5% Topical Cream
Normalized name: Aldara 5% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Imiquimod cream (1 sachet) will be administered via menstrual cup, before going to sleep, 3 times per week for 16 weeks. Menstrual cup will be inserted in the vagina for a duration of 6-8 hours. In case of severe side effects applications can be reduced to twice per week and if side effects are persistent, to once per week. For maximum control of cervical disease, control colposcopy with a PAP smear and a punch biopsy will be scheduled at 10 weeks to rule out progression, and at 20 weeks after treatment initiation to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present, and if there are any new lesions present, additional biopsies will be performed. In case of disease progression or persistence, treatment with LLETZ will be offered.
Study: NCT03616405
Drug: rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
Study: NCT03419403
Drug: Vasoconstrictor eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, eye drop
Study: NCT04644809
Drug: LY3561774
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04644809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT00835692
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg Tablet
Study: NCT00835692
Drug: Biaxin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Tablet
Study: NCT02868242
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT03193398
Drug: Placebo oral capsule(s)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered once daily to patients with MDD for 8 weeks
Study: NCT00646542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01695473
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
Study: NCT00557219
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
Study: NCT00245115
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03730272
Drug: analgesic drugs and methods
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patient will receive analgesic treatment at the discretion of the physician in charge
Study: NCT00556660
Drug: [123I] AV-151
Approvals — FDA: no, EMA: no, PMDA: no
Description: To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects
Study: NCT02211924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04329195
Drug: 2: continuation of RAS blocker therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuation of RAS blocker therapy
Study: NCT00525759
Drug: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
Study: NCT00525759
Drug: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
Study: NCT01718873
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
Study: NCT01075282
Drug: LY2189265
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02217267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01365663
Drug: SPC4955
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Weekly SC injections
Study: NCT01365663
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Weekly SC injections
Study: NCT01289015
Drug: NAFT-600 ( naftin 2 % gel )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical; applied once daily for two weeks
Study: NCT01289015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical; applied once daily for two weeks
Study: NCT00649532
Drug: Zofran® Tablets 24 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24mg, single dose fasting
Study: NCT00283595
Drug: Placebo for Recombinant Human Growth Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks
Study: NCT02961556
Drug: AJG555
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 to 6 sachets daily per participants' age and conditions.
Study: NCT00290433
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 1: 300 mg/m\^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
Study: NCT00290433
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 1 and 2: 200 mg/m\^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m\^2 IV Over 22 Hours on Day 1.
Study: NCT04294823
Drug: Nexium Pill
Normalized name: Nexium Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast Nexium mups 40 mg will be discontinued after Day 28.
Study: NCT00003470
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults with an anaplastic astrocytoma that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01019421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on treatment to donepezil
Study: NCT00701675
Drug: Placebo 50 or 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg or 100mg matching placebo
Study: NCT01660932
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01356914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
Study: NCT02796378
Drug: Training+Simvastatin+Q10-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10-placebo.
Study: NCT02796378
Drug: Training+Simvastatin-placebo+Q10-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin-placebo and Q10-placebo.
Study: NCT02796378
Drug: Training+Simvastatin+Q10
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10 400 mg/day.
Study: NCT00669721
Drug: law molecular weigth heparin
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
Study: NCT00669721
Drug: unfractioned heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
Study: NCT04304209
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, bid, qd1-14, q3w, in Capeox regimen, oral administration
Study: NCT00171288
Drug: fluvastatin, ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05386069
Drug: NOMO Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weight-based ketamine bolus (0.5 mg/kg) at procedure start, no Opioid rescue medications
Study: NCT02967029
Drug: Remifentanil Hydrochloride
Normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the influence of remifentanyl as a hypotensive agent on rSO2
Study: NCT02071160
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
Study: NCT00686933
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take up to 80 mg daily for 24 months
Study: NCT01879345
Drug: BIA 2-093 - 1800 mg (Group 1)
Normalized name: meningococcal group B vaccine 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets of BIA 2-093
Study: NCT01879345
Drug: BIA 2-093 - 2400 mg (Group 2)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets of BIA 2-093 600 mg
Study: NCT01879345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets
Study: NCT01965301
Drug: BP1.5375 suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT01965301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT02929264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, single dose
Study: NCT00239876
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02876887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01814514
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02512588
Drug: BTD-001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02512588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01058096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.
Study: NCT02870361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00106886
Drug: Folic acid, vitamin B6 and B12 or placebo
Approvals — FDA: no, EMA: no, PMDA: no